Targeting podocyte-associated diseases

Advanced Drug Delivery Reviews

Volumn 62, Issue 14, 2010, Pages 1325-1336

  Leeuwis, Jan Willem ^a   Nguyen, Tri Q ^a   Dendooven, Amélie ^a   Kok, Robbert J ^b   Goldschmeding, Roel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Animal models; Drug delivery; Drug targeting; Glomerular disease; Kidney; Nephron; Podocyte

Indexed keywords

ANIMAL MODEL; DRUG-TARGETING; GLOMERULAR DISEASE; KIDNEY; NEPHRON; PODOCYTE;

ANIMALS; DIAPHRAGMS; DRUG DELIVERY; ENDOTHELIAL CELLS; GENES;

DISEASES;

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; ALPHAVBETA3 INTEGRIN INHIBITOR; C MAF INDUCING PROTEIN; CATHEPSIN L; CELL PROTEIN; CYCLOSPORIN A; DALTEPARIN; DIBENZAZEPINE; FC RECEPTOR; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NOTCH RECEPTOR; OSTEOGENIC PROTEIN 1; PROTEIN INHIBITOR; PROTEIN KINASE C ALPHA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VITRONECTIN RECEPTOR;

APOPTOSIS; BOWMAN CAPSULE; CELL INTERACTION; DIABETIC NEPHROPATHY; DRUG TARGETING; ENDOTHELIUM CELL; EXPERIMENTAL ANIMAL; FOOD PROCESSING; GENE TARGETING; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS EPITHELIUM; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PERMEABILITY BARRIER; PODOCYTE; PODOCYTOPATHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; GLOMERULAR BASEMENT MEMBRANE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MICE; MOLECULAR TARGETED THERAPY; PODOCYTES;

EID: 78649446025     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.08.012     Document Type: Review

References (125)

1. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.
2. Meguid El Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
3. Quaglia M., Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs 2009, 69:1303-1317.
4. Dolman M.E.M., Fretz M.M., Segers G.J.W., Lacombe M., Prakash J., Storm G., Hennink W.E., Kok R.J. Renal targeting of kinase inhibitors. Int. J. Pharm. 2008, 364:249-257.
5. Dressler G.R. The cellular basis of kidney development. Annu. Rev. Cell Dev. Biol. 2006, 22:509-529.
6. Mundel P., Reiser J. Proteinuria: an enzymatic disease of the podocyte?. Kidney Int. 2010, 77:571-580.
7. Reiser J., von Gersdorff G., Loos M., Oh J., Asanuma K., Giardino L., Rastaldi M.P., Calvaresi N., Watanabe H., Schwarz K., Faul C., Kretzler M., Davidson A., Sugimoto H., Kalluri R., Sharpe A.H., Kreidberg J.A., Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 2004, 113:1390-1397.
8. D'Agati V.D. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). Kidney Int. 2008, 73:399-406.
9. Shankland S.J. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006, 69:2131-2147.
10. Ronco P. Proteinuria: is it all in the foot?. J. Clin. Invest. 2007, 117:2079-2082.
11. Akilesh S., Huber T.B., Wu H., Wang G., Hartleben B., Krishnan J.B., Miner J.H., Roopenian D.C., Unanue E.R., Shaw A.S. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:967-972.
12. Eyre J., Ioannou K., Grubb B.D., Saleem M.A., Mathieson P.W., Brunskill N.J., Christensen E.I., Topham P.S. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am. J. Physiol. Ren. Physiol. 2007, 292:F674-F681.
13. Hauser P.V., Pippin J.W., Kaiser C., Krofft R.D., Brinkkoetter P.T., Hudkins K.L., Kerjaschki D., Reiser J., Alpers C.E., Shankland S.J. Novel siRNA delivery system to target podocytes in vivo. PLoS ONE 2010, 5:e9463.
14. Tryggvason K., Patrakka J., Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N. Engl. J. Med. 2006, 354:1387-1401.
15. Lavin P.J., Gbadegesin R., Damodaran T.V., Winn M.P. Therapeutic targets in focal and segmental glomerulosclerosis. Curr. Opin. Nephrol. Hypertens. 2008, 17:386-392.
16. Chuang P.Y., He J.C. Signaling in regulation of podocyte phenotypes. Nephron Physiol. 2009, 111:9-15.
17. Kwoh C., Shannon M.B., Miner J.H., Shaw A. Pathogenesis of nonimmune glomerulopathies. Annu. Rev. Pathol. Mech. Dis. 2006, 1:349-374.
18. Huber T.B., Hartleben B., Kim J., Schmidts M., Schermer B., Keil A., Egger L., Lecha R.L., Borner C., Pavenstädt H., Shaw A.S., Walz G., Benzing T. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol. Cell. Biol. 2003, 23:4917-4928.
19. Verma R., Kovari I., Soofi A., Nihalani D., Patrie K., Holzman L.B. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J. Clin. Invest. 2006, 116:1346-1359.
20. Benzing T. The promise of well-being: stay in shape with N(i)ck. J. Am. Soc. Nephrol. 2009, 20:1425-1427.
21. Jones N., New L.A., Fortino M.A., Eremina V., Ruston J., Blasutig I.M., Aoudjit L., Zou Y., Liu X., Yu G.-L., Takano T., Quaggin S.E., Pawson T. Nck proteins maintain the adult glomerular filtration barrier. J. Am. Soc. Nephrol. 2009, 20:1533-1543.
22. Schwarz K., Simons M., Reiser J., Saleem M.A., Faul C., Kriz W., Shaw A.S., Holzman L.B., Mundel P. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J. Clin. Invest. 2001, 108:1621-1629.
23. Möller C.C., Flesche J., Reiser J. Sensitizing the slit diaphragm with TRPC6 ion channels. J. Am. Soc. Nephrol. 2009, 20:950-953.
24. Asanuma K., Kim K., Oh J., Giardino L., Chabanis S., Faul C., Reiser J., Mundel P. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J. Clin. Invest. 2005, 115:1188-1198.
25. Asanuma K., Yanagida-Asanuma E., Faul C., Tomino Y., Kim K., Mundel P. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat. Cell Biol. 2006, 8:485-491.
26. Schlöndorff D., Banas B. The mesangial cell revisited: no cell is an island. J. Am. Soc. Nephrol. 2009, 20:1179-1187.
27. Ichimura K., Stan R.V., Kurihara H., Sakai T. Glomerular endothelial cells form diaphragms during development and pathologic conditions. J. Am. Soc. Nephrol. 2008, 19:1463-1471.
28. Segal M.S., Baylis C., Johnson R.J. Endothelial health and diversity in the kidney. J. Am. Soc. Nephrol. 2006, 17:323-324.
29. Satchell S.C., Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am. J. Physiol. Ren. Physiol. 2009, 296:F947-F956.
30. Weinbaum S., Tarbell J.M., Damiano E.R. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 2007, 9:121-167.
31. Deen W.M., Lazzara M.J., Myers B.D. Structural determinants of glomerular permeability. Am. J. Physiol. Ren. Physiol. 2001, 281:F579-F596.
32. Gubler M.C. Inherited diseases of the glomerular basement membrane. Nat. Clin. Pract. Nephrol. 2008, 4:24-37.
33. Ohse T., Pippin J.W., Chang A.M., Krofft R.D., Miner J.H., Vaughan M.R., Shankland S.J. The enigmatic parietal epithelial cell is finally getting noticed: a review. Kidney Int. 2009, 76:1225-1238.
34. Appel D., Kershaw D.B., Smeets B., Yuan G., Fuss A., Frye B., Elger M., Kriz W., Floege J., Moeller M.J. Recruitment of podocytes from glomerular parietal epithelial cells. J. Am. Soc. Nephrol. 2009, 20:333-343.
35. Ronconi E., Sagrinati C., Angelotti M.L., Lazzeri E., Mazzinghi B., Ballerini L., Parente E., Becherucci F., Gacci M., Carini M., Maggi E., Serio M., Vannelli G.B., Lasagni L., Romagnani S., Romagnani P. Regeneration of glomerular podocytes by human renal progenitors. J. Am. Soc. Nephrol. 2009, 20:322-332.
36. Wiggins R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007, 71:1205-1214.
37. Barisoni L., Schnaper H.W., Kopp J.B. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin. J. Am. Soc. Nephrol. 2007, 2:529-542.
38. Barisoni L., Schnaper H.W., Kopp J.B. Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch. Pathol. Lab. Med. 2009, 133:201-216.
39. Reiser J., Gupta V., Kistler A.D. Toward the development of podocyte-specific drugs. Kidney Int. 2010, 77:662-668.
40. Albaqumi M., Barisoni L. Current views on collapsing glomerulopathy. J. Am. Soc. Nephrol. 2008, 19:1276-1281.
41. Smeets B., Angelotti M.L., Rizzo P., Dijkman H., Lazzeri E., Mooren F., Ballerini L., Parente E., Sagrinati C., Mazzinghi B., Ronconi E., Becherucci F., Benigni A., Steenbergen E.J., Lasagni L., Rodrigues Díez G., Wetzels J., Romagnani P. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J. Am. Soc. Nephrol. 2009, 20:2593-2603.
42. Smeets B., Dijkman H.B.P.M., Wetzels J.F.M., Steenbergen E.J. Lessons from studies on focal segmental glomerulosclerosis: an important role for parietal epithelial cells?. J. Pathol. 2006, 210:263-272.
43. D'Agati V.D. The spectrum of focal segmental glomerulosclerosis: new insights. Curr. Opin. Nephrol. Hypertens. 2008, 17:271-281.
44. Korgaonkar S.N., Feng X., Ross M.D., Lu T.-C., D'Agati V., Iyengar R., Klotman P.E., He J.C. HIV-1 upregulates VEGF in podocytes. J. Am. Soc. Nephrol. 2008, 19:877-883.
45. Ronco P., Debiec H. Membranous glomerulopathy: the evolving story. Curr. Opin. Nephrol. Hypertens. 2010, 19:254-259.
46. Glassock R.J. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am. J. Kidney Dis. 2010, 56:157-167.
47. Kerjaschki D., Farquhar M.G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:5557-5561.
48. Debiec H., Guigonis V., Mougenot B., Decobert F., Haymann J.-P., Bensman A., Deschênes G., Ronco P.M. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 2002, 346:2053-2060.
49. Beck L.H., Bonegio R.G.B., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., Klein J.B., Salant D.J. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009, 361:11-21.
50. Wolf G., Chen S., Ziyadeh F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
51. Reddy G.R., Kotlyarevska K., Ransom R.F., Menon R.K. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?. Curr. Opin. Nephrol. Hypertens. 2008, 17:32-36.
52. Li J.J., Kwak S.J., Jung D.S., Kim J.J., Yoo T.H., Ryu D.R., Han S.H., Choi H.Y., Lee J.E., Moon S.J., Kim D.K., Han D.S., Kang S.W. Podocyte biology in diabetic nephropathy. Kidney Int. 2007, 72:S36-S42.
53. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G., Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002, 51:3090-3094.
54. Pippin J.W., Brinkkoetter P.T., Cormack-Aboud F.C., Durvasula R.V., Hauser P.V., Kowalewska J., Krofft R.D., Logar C.M., Marshall C.B., Ohse T., Shankland S.J. Inducible rodent models of acquired podocyte diseases. Am. J. Physiol. Ren. Physiol. 2009, 296:F213-F229.
55. Nagata M., Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992, 42:148-160.
56. Olson J.L., Hostetter T.H., Rennke H.G., Brenner B.M., Venkatachalam M.A. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 1982, 22:112-126.
57. Frenk S., Antonowicz I., Craig J., Metcoff J. Experimental nephrotic syndrome induced in rats by aminonucleoside; renal lesions and body electrolyte composition. Proc. Soc. Exp. Biol. Med. 1955, 89:424-427.
58. Okuda S., Oh Y., Tsuruda H., Onoyama K., Fujimi S., Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 1986, 29:502-510.
59. Wharram B.L., Goyal M., Wiggins J.E., Sanden S.K., Hussain S., Filipiak W.E., Saunders T.L., Dysko R.C., Kohno K., Holzman L.B., Wiggins R.C. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J. Am. Soc. Nephrol. 2005, 16:2941-2952.
60. Pollak M.R. Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J. Am. Soc. Nephrol. 2002, 13:3016-3023.
61. Löwik M.M., Groenen P.J.T.A., Pronk I., Lilien M.R., Goldschmeding R., Dijkman H.B., Levtchenko E.N., Monnens L.A., van den Heuvel L.P. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int. 2007, 72:1198-1203.
62. Löwik M.M., Groenen P.J., Levtchenko E.N., Monnens L.A., van den Heuvel L.P. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis-a review. Eur. J. Pediatr. 2009, 168:1291-1304.
63. Shih N.Y., Li J., Karpitskii V., Nguyen A., Dustin M.L., Kanagawa O., Miner J.H., Shaw A.S. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999, 286:312-315.
64. Kaplan J.M., Kim S.H., North K.N., Rennke H., Correia L.A., Tong H.Q., Mathis B.J., Rodríguez-Pérez J.C., Allen P.G., Beggs A.H., Pollak M.R. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet. 2000, 24:251-256.
65. Henderson J.M., Al-Waheeb S., Weins A., Dandapani S.V., Pollak M.R. Mice with altered alpha-actinin-4 expression have distinct morphologic patterns of glomerular disease. Kidney Int. 2008, 73:741-750.
66. Lu T.-C., He J.C., Klotman P. Animal models of HIV-associated nephropathy. Curr. Opin. Nephrol. Hypertens. 2006, 15:233-237.
67. Bruggeman L.A., Dikman S., Meng C., Quaggin S.E., Coffman T.M., Klotman P.E. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 1997, 100:84-92.
68. Zhong J., Zuo Y., Ma J., Fogo A.B., Jolicoeur P., Ichikawa I., Matsusaka T. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 2005, 68:1048-1060.
69. Barisoni L., Madaio M.P., Eraso M., Gasser D.L., Nelson P.J. The kd/kd mouse is a model of collapsing glomerulopathy. J. Am. Soc. Nephrol. 2005, 16:2847-2851.
70. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.-P., Kikkawa Y., Miner J.H., Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003, 111:707-716.
71. Chen J.-S., Chen A., Chang L.-C., Chang W.-S.W., Lee H.-S., Lin S.-H., Lin Y.-F. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. Nephrol. Dial. Transplant. 2004, 19:2721-2728.
72. Brosius F.C., Alpers C.E., Bottinger E.P., Breyer M.D., Coffman T.M., Gurley S.B., Harris R.C., Kakoki M., Kretzler M., Leiter E.H., Levi M., Mcindoe R.A., Sharma K., Smithies O., Susztak K., Takahashi N., Takahashi T. Mouse Models of Diabetic Nephropathy. J. Am. Soc. Nephrol. 2009, 20:2503-2512.
73. Schlöndorff D. Choosing the right mouse model for diabetic nephropathy. Kidney Int. 2010, 77:749-750.
74. Tesch G.H., Allen T.J. Rodent models of streptozotocin-induced diabetic nephropathy (Methods in Renal Research). Nephrology 2007, 12:261-266.
75. Gurley S.B., Clare S.E., Snow K.P., Hu A., Meyer T.W., Coffman T.M. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Ren. Physiol. 2006, 290:F214-F222.
76. Myint K.-M., Yamamoto Y., Doi T., Kato I., Harashima A., Yonekura H., Watanabe T., Shinohara H., Takeuchi M., Tsuneyama K., Hashimoto N., Asano M., Takasawa S., Okamoto H., Yamamoto H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006, 55:2510-2522.
77. Takamura T., Kato I., Kimura N., Nakazawa T., Yonekura H., Takasawa S., Okamoto H. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J. Biol. Chem. 1998, 273:2493-2496.
78. Breyer M.D., Qi Z., Tchekneva E. Diabetic nephropathy: leveraging mouse genetics. Curr. Opin. Nephrol. Hypertens. 2006, 15:227-232.
79. Sharma K., McCue P., Dunn S.R. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Ren. Physiol. 2003, 284:F1138-F1144.
80. Hudkins K.L., Pichaiwong W., Wietecha T., Kowalewska J., Banas M.C., Spencer M.W., Mühlfeld A., Koelling M., Pippin J.W., Shankland S.J., Askari B., Rabaglia M.E., Keller M.P., Attie A.D., Alpers C.E. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:1533-1542.
81. Ishola D.A., van der Giezen D.M., Hahnel B., Goldschmeding R., Kriz W., Koomans H.A., Joles J.A. In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. Nephrol. Dial. Transplant. 2006, 21:591-597.
82. Eddy A.A. Interstitial nephritis induced by protein-overload proteinuria. Am. J. Pathol. 1989, 135:719-733.
83. Seiler M.W., Venkatachalam M.A., Cotran R.S. Glomerular epithelium: structural alterations induced by polycations. Science 1975, 189:390-393.
84. Tuffin G., Huwyler J., Waelti E., Hammer C., Marti H.-P. Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat. J. Drug Target. 2008, 16:156-166.
85. Tuffin G., Waelti E., Huwyler J., Hammer C., Marti H.-P. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol. 2005, 16:3295-3305.
86. Scindia Y., Deshmukh U., Thimmalapura P.-R., Bagavant H. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 2008, 58:3884-3891.
87. Shimizu H., Hori Y., Kaname S., Yamada K., Nishiyama N., Matsumoto S., Miyata K., Oba M., Yamada A., Kataoka K., Fujita T. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 2010, 21:622-633.
88. Asgeirsdóttir S.A., Zwiers P.J., Morselt H.W., Moorlag H.E., Bakker H.I., Heeringa P., Kok J.W., Kallenberg C.G.M., Molema G., Kamps J.A.A.M. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Ren. Physiol. 2008, 294:F554-F561.
89. Asgeirsdóttir S.A., Talman E.G., de Graaf I.A., Kamps J.A.A.M., Satchell S.C., Mathieson P.W., Ruiters M.H.J., Molema G. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro-a quantitative study. J. Control. Release 2010, 141:241-251.
90. Temming K., Schiffelers R.M., Molema G., Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 2005, 8:381-402.
91. Shankland S.J., Pippin J.W., Reiser J., Mundel P. Podocytes in culture: past, present, and future. Kidney Int. 2007, 72:26-36.
92. Yamauchi K., Takano Y., Kasai A., Hayakawa K., Hiramatsu N., Enomoto N., Yao J., Kitamura M. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int. 2006, 70:892-900.
93. Tossidou I., Teng B., Menne J., Shushakova N., Park J.-K., Becker J.U., Modde F., Leitges M., Haller H., Schiffer M. Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis. PLoS ONE 2010, 5:e10185.
94. Menne J., Park J.-K., Boehne M., Elger M., Lindschau C., Kirsch T., Meier M., Gueler F., Fiebeler A., Bahlmann F.H., Leitges M., Haller H. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004, 53:2101-2109.
95. Zhang S.-Y., Kamal M., Dahan K., Pawlak A., Ory V., Desvaux D., Audard V., Candelier M., Mohamed F.B., Matignon M., Christov C., Decrouy X., Bernard V., Mangiapan G., Lang P., Guellaën G., Ronco P., Sahali D. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci. Signal. 2010, 3:ra39.
96. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., Chang J.-M., Choi H.Y., Campbell K.N., Kim K., Reiser J., Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 2008, 14:931-938.
97. Sever S., Altintas M.M., Nankoe S.R., Möller C.C., Ko D., Wei C., Henderson J., del Re E.C., Hsing L., Erickson A., Cohen C.D., Kretzler M., Kerjaschki D., Rudensky A., Nikolic B., Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 2007, 117:2095-2104.
98. Reiser J., Oh J., Shirato I., Asanuma K., Hug A., Mundel T.M., Honey K., Ishidoh K., Kominami E., Kreidberg J.A., Tomino Y., Mundel P. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J. Biol. Chem. 2004, 279:34827-34832.
99. Baricos W.H., O'Connor S.E., Cortez S.L., Wu L.T., Shah S.V. The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochem. Biophys. Res. Commun. 1988, 155:1318-1323.
100. Wei C., Möller C.C., Altintas M.M., Li J., Schwarz K., Zacchigna S., Xie L., Henger A., Schmid H., Rastaldi M.P., Cowan P., Kretzler M., Parrilla R., Bendayan M., Gupta V., Nikolic B., Kalluri R., Carmeliet P., Mundel P., Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 2008, 14:55-63.
101. Niranjan T., Murea M., Susztak K. The pathogenic role of Notch activation in podocytes. Nephron Exp. Nephrol. 2009, 111:e73-e79.
102. Niranjan T., Bielesz B., Gruenwald A., Ponda M., Krishnan J.B., Thomas D., Susztak K. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med. 2008, 14:290-298.
103. Hoffmann S., Podlich D., Hähnel B., Kriz W., Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol. 2004, 15:1475-1487.
104. Crowley S.D., Gurley S.B., Herrera M.J., Ruiz P., Griffiths R., Kumar A.P., Kim H.-S., Smithies O., Le T.H., Coffman T.M. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17985-17990.
105. Le T.H., Coffman T.M. Targeting genes in the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 2008, 17:57-63.
106. Ichihara A., Sakoda M., Kurauchi-Mito A., Kaneshiro Y., Itoh H. Renin, prorenin and the kidney: a new chapter in an old saga. J. Nephrol. 2009, 22:306-311.
107. Ichihara A., Hayashi M., Kaneshiro Y., Suzuki F., Nakagawa T., Tada Y., Koura Y., Nishiyama A., Okada H., Uddin M.N., Nabi A.H.M.N., Ishida Y., Inagami T., Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest. 2004, 114:1128-1135.
108. Sakoda M., Ichihara A., Kurauchi-Mito A., Narita T., Kinouchi K., Murohashi-Bokuda K., Saleem M.A., Nishiyama A., Suzuki F., Itoh H. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am. J. Hypertens. 2010, 23:575-580.
109. Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am. J. Kidney Dis. 2010, 55:928-940.
110. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D., Schmidt A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 2003, 162:1123-1137.
111. Tan A.L.Y., Sourris K.C., Harcourt B.E., Thallas-Bonke V., Penfold S., Andrikopoulos S., Thomas M.C., O'Brien R.C., Bierhaus A., Cooper M.E., Forbes J.M., Coughlan M.T. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2010, 298:F763-F770.
112. Jensen L.J.N., Denner L., Schrijvers B.F., Tilton R.G., Rasch R., Flyvbjerg A. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 2006, 188:493-501.
113. De Petris L., Hruska K.A., Chiechio S., Liapis H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol. Dial. Transplant. 2007, 22:3442-3450.
114. Gould S.E., Day M., Jones S.S., Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int. 2002, 61:51-60.
115. Turk T., Leeuwis J.W., Gray J., Torti S.V., Lyons K.M., Nguyen T.Q., Goldschmeding R. BMP Signaling and Podocyte Markers Are Decreased in Human Diabetic Nephropathy in Association With CTGF Overexpression. J. Histochem. Cytochem. 2009, 57:623-631.
116. Wang S.N., de Caestecker M., Krishnan J.B., Mitu G.M., Lapage J., Hirschberg R.R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 2006, 17:2504-2512.
117. Wang S., Chen Q., Simon T.C., Strebeck F., Chaudhary L., Morrissey J., Liapis H., Klahr S., Hruska K.A. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 2003, 63:2037-2049.
118. Nguyen T.Q., Roestenberg P., van Nieuwenhoven F.A., Bovenschen N., Li Z., Xu L., Oliver N., Aten J., Joles J.A., Vial C., Brandan E., Lyons K.M., Goldschmeding R. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:2098-2107.
119. Guha M., Xu Z., Tung D., Lanting L., Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007, 21:3355-3368.
120. Ku C.-H., White K.E., Dei Cas A., Hayward A., Webster Z., Bilous R., Marshall S., Viberti G., Gnudi L. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008, 57:2824-2833.
121. Kosugi T., Nakayama T., Li Q., Chiodo V.A., Zhang L., Campbell-Thompson M., Grant M., Croker B.P., Nakagawa T. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am. J. Physiol. Ren. Physiol. 2010, 298:F609-F616.
122. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 2006, 17:3093-3104.
123. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J.B., Kabir M.G., Backx P.H., Gerber H.-P., Ferrara N., Barisoni L., Alpers C.E., Quaggin S.E. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008, 358:1129-1136.
124. Izzedine H., Massard C., Spano J.P., Goldwasser F., Khayat D., Soria J.C. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur. J. Cancer 2010, 46:439-448.
125. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.